메뉴 건너뛰기




Volumn 341, Issue 5, 2011, Pages 388-393

Dyslipidemia intervention in metabolic syndrome: Emphasis on improving lipids and clinical event reduction

Author keywords

Coronary heart disease; HDL; Metabolic syndrome; Obesity; Triglycerides

Indexed keywords

ATORVASTATIN; COLESEVELAM; DOCOSAHEXAENOIC ACID; EZETIMIBE; FENOFIBRATE; FENOFIBRIC ACID; FISH OIL; GEMFIBROZIL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; TRIACYLGLYCEROL;

EID: 79955513114     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31821483fa     Document Type: Review
Times cited : (26)

References (67)
  • 1
    • 49249100260 scopus 로고    scopus 로고
    • A practical "aBCDE" approach to the metabolic syndrome
    • Blaha MJ, Bansal S, Rouf R, et al. A practical "ABCDE" approach to the metabolic syndrome. Mayo Clin Proc 2008;83:932-43.
    • (2008) Mayo Clin Proc , vol.83 , pp. 932-943
    • Blaha, M.J.1    Bansal, S.2    Rouf, R.3
  • 3
    • 16844384330 scopus 로고    scopus 로고
    • Cardiac rehabilitation and exercise training programs in metabolic syndrome and diabetes
    • Lavie CJ, Milani RV. Cardiac rehabilitation and exercise training programs in metabolic syndrome and diabetes. J Cardiopulm Rehabil 2005;25:59-66.
    • (2005) J Cardiopulm Rehabil , vol.25 , pp. 59-66
    • Lavie, C.J.1    Milani, R.V.2
  • 4
    • 0842277242 scopus 로고    scopus 로고
    • Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/ American Heart Association conference on scientific issues related to definition
    • DOI 10.1161/01.CIR.0000111245.75752.C6
    • Brewer SM, Grundy HB Jr, Cleeman JI, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/ American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-8. (Pubitemid 38133916)
    • (2004) Circulation , vol.109 , Issue.3 , pp. 433-438
    • Grundy, S.M.1    Brewer Jr., H.B.2    Cleeman, J.I.3    Smith Jr., S.C.4    Lenfant, C.5
  • 5
    • 0031851293 scopus 로고    scopus 로고
    • Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation
    • DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
    • Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53. (Pubitemid 28319935)
    • (1998) Diabetic Medicine , vol.15 , Issue.7 , pp. 539-553
    • Alberti, K.G.M.M.1    Zimmet, P.Z.2
  • 6
    • 0035897696 scopus 로고    scopus 로고
    • Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, Executive and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
    • Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, Executive And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
    • (2001) JAMA , vol.285 , pp. 2486-2497
  • 7
    • 70350245011 scopus 로고    scopus 로고
    • Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention
    • National Heart, Lung, and Blood Institute; American Heart Association;i World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity
    • Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120: 1640-5.
    • (2009) Circulation , vol.120 , pp. 1640-1645
    • Alberti, K.G.1    Eckel, R.H.2    Grundy, S.M.3
  • 9
    • 65549109680 scopus 로고    scopus 로고
    • Obesity and cardiovascular disease: Risk factor, paradox, and impact of weight loss
    • Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009;53:1925-32.
    • (2009) J Am Coll Cardiol , vol.53 , pp. 1925-1932
    • Lavie, C.J.1    Milani, R.V.2    Ventura, H.O.3
  • 10
    • 4644279733 scopus 로고    scopus 로고
    • Increasing prevalence of the metabolic syndrome among U.S. adults
    • DOI 10.2337/diacare.27.10.2444
    • Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. Adults. Diabetes Care 2004;27: 2444-9. (Pubitemid 39281399)
    • (2004) Diabetes Care , vol.27 , Issue.10 , pp. 2444-2449
    • Ford, E.S.1    Giles, W.H.2    Mokdad, A.H.3
  • 11
    • 0037861906 scopus 로고    scopus 로고
    • Prevalence and profile of metabolic syndrome in patients following acute coronary events and effects of therapeutic lifestyle change with cardiac rehabilitation
    • DOI 10.1016/S0002-9149(03)00464-8
    • Milani RV, Lavie CJ. Prevalence and profile of metabolic syndrome in patients following acute coronary events and effects of therapeutic lifestyle change with cardiac rehabilitation. Am J Cardiol 2003;92: 50-4. (Pubitemid 36782309)
    • (2003) American Journal of Cardiology , vol.92 , Issue.1 , pp. 50-54
    • Milani, R.V.1    Lavie, C.J.2
  • 12
    • 34247193564 scopus 로고    scopus 로고
    • Metabolic syndrome: Is it a syndrome? Does it matter?
    • DOI 10.1161/CIRCULATIONAHA.106.658336, PII 0000301720070403000017
    • Kahn R. Metabolic syndrome: is it a syndrome? Does it matter? Circulation 2007;115:1806-10. (Pubitemid 46648618)
    • (2007) Circulation , vol.115 , Issue.13 , pp. 1806-1810
    • Kahn, R.1
  • 13
    • 33746429613 scopus 로고    scopus 로고
    • Does the metabolic syndrome exist?
    • DOI 10.2337/dc05-2307
    • Grundy SM. Does the metabolic syndrome exist? Diabetes Care 2006;29:1689-92. (Pubitemid 44127605)
    • (2006) Diabetes Care , vol.29 , Issue.7 , pp. 1689-1692
    • Grundy, S.M.1
  • 14
    • 34547327365 scopus 로고    scopus 로고
    • The individual components of the metabolic syndrome: Is there a raison d'etre?
    • Reaven GM. The individual components of the metabolic syndrome: is there a raison d'etre? J Am Coll Nutr 2007;26:191-5. (Pubitemid 47134700)
    • (2007) Journal of the American College of Nutrition , vol.26 , Issue.3 , pp. 191-195
    • Reaven, G.M.1
  • 15
    • 33748364584 scopus 로고    scopus 로고
    • Clinical use of the metabolic syndrome: Why the confusion?
    • Blaha M, Elasy TA. Clinical use of the metabolic syndrome: why the confusion? Clin Diabetes 2006;24:125-31.
    • (2006) Clin Diabetes , vol.24 , pp. 125-1231
    • Blaha, M.1    Elasy, T.A.2
  • 18
    • 4444222221 scopus 로고    scopus 로고
    • Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults
    • DOI 10.1161/01.CIR.0000140677.20606.0E
    • Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004;110: 1245-50. (Pubitemid 39202340)
    • (2004) Circulation , vol.110 , Issue.10 , pp. 1245-1250
    • Malik, S.1    Wong, N.D.2    Franklin, S.S.3    Kamath, T.V.4    L'Italien, G.J.5    Pio, J.R.6    Williams, G.R.7
  • 19
    • 0037407403 scopus 로고    scopus 로고
    • NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older
    • DOI 10.2337/diabetes.52.5.1210
    • Alexander CM, Landsman PB, Teutsch SM, et al. Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003;52: 1210-4. (Pubitemid 36523358)
    • (2003) Diabetes , vol.52 , Issue.5 , pp. 1210-1214
    • Alexander, C.M.1    Landsman, P.B.2    Teutsch, S.M.3    Haffner, S.M.4
  • 20
    • 79955521241 scopus 로고    scopus 로고
    • The impact of gemfibrizol, niacin and cholestyramine combination therapy on metabolic syndrome in the Armed Forces Regression Study
    • Krasuski RA, Devendra GP, Cater G, et al. The impact of gemfibrizol, niacin and cholestyramine combination therapy on metabolic syndrome in the Armed Forces Regression Study. Am J Med Sci 2011;341:xxx-xxx.
    • (2011) Am J Med Sci , vol.341
    • Krasuski, R.A.1    Devendra, G.P.2    Cater, G.3
  • 21
    • 37449029988 scopus 로고    scopus 로고
    • Shedding light on high-density lipoprotein cholesterol: The post-ILLUMINATE era
    • Lavie CJ, Milani RV. Shedding light on high-density lipoprotein cholesterol: the post-ILLUMINATE era. J Am Coll Cardiol 2008;51: 56-8.
    • (2008) J Am Coll Cardiol , vol.51 , pp. 56-58
    • Lavie, C.J.1    Milani, R.V.2
  • 22
    • 59049091800 scopus 로고    scopus 로고
    • The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: A new era in atherosclerosis management
    • Cardenas GA, Lavie CJ, Cardenas V, et al. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management. Rev Cardiovasc Med 2008;9:239-58.
    • (2008) Rev Cardiovasc Med , vol.9 , pp. 239-258
    • Cardenas, G.A.1    Lavie, C.J.2    Cardenas, V.3
  • 23
    • 33846637379 scopus 로고    scopus 로고
    • Triglycerides and the risk of coronary heart disease: 10 158 Incident cases among 262 525 participants in 29 Western prospective studies
    • DOI 10.1161/CIRCULATIONAHA.106.637793, PII 0000301720070130000007
    • Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007;115: 450-8. (Pubitemid 46184196)
    • (2007) Circulation , vol.115 , Issue.4 , pp. 450-458
    • Sarwar, N.1    Danesh, J.2    Eiriksdottir, G.3    Sigurdsson, G.4    Wareham, N.5    Bingham, S.6    Boekholdt, S.M.7    Khaw, K.-T.8    Gudnason, V.9
  • 25
    • 77951719670 scopus 로고    scopus 로고
    • Using apolipoprotein B to manage dyslipidemic patients: Time for a change?
    • Harper CR, Jacobson TA. Using apolipoprotein B to manage dyslipidemic patients: time for a change? Mayo Clin Proc 2010;85:440-5.
    • (2010) Mayo Clin Proc , vol.85 , pp. 440-445
    • Harper, C.R.1    Jacobson, T.A.2
  • 26
    • 77951745342 scopus 로고    scopus 로고
    • To B or not to B: Is non-highdensity lipoprotein cholesterol an adequate surrogate for apolipoprotein B?
    • Lavie CJ, Milani RV, O'Keefe JH. To B or not to B: is non-highdensity lipoprotein cholesterol an adequate surrogate for apolipoprotein B? Mayo Clin Proc 2010;85:446-50.
    • (2010) Mayo Clin Proc , vol.85 , pp. 446-450
    • Lavie, C.J.1    Milani, R.V.2    O'Keefe, J.H.3
  • 27
    • 3142729178 scopus 로고    scopus 로고
    • Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
    • DOI 10.1161/01.CIR.0000133317.49796.0E
    • Grundy SM, Cleeman JL, Mercz CN, et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines [published correction appears in Circulation. 2004;110(6): 763]. Circulation 2004;110:227-39. (Pubitemid 38924592)
    • (2004) Circulation , vol.110 , Issue.2 , pp. 227-239
    • Grundy, S.M.1    Cleeman, J.I.2    Bairey Merz, C.N.3    Brewer Jr., H.B.4    Clark, L.T.5    Hunninghake, D.B.6    Pasternak, R.C.7    Smith Jr., S.C.8    Stone, N.J.9
  • 28
    • 58249086417 scopus 로고    scopus 로고
    • Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk
    • Robinson JG, Wang S, Smith BJ, et al. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol 2009;53:316-22.
    • (2009) J Am Coll Cardiol , vol.53 , pp. 316-322
    • Robinson, J.G.1    Wang, S.2    Smith, B.J.3
  • 29
    • 72549104133 scopus 로고    scopus 로고
    • Are you targeting non high-density lipoprotein cholesterol [editorial]?
    • Robinson JG. Are you targeting non high-density lipoprotein cholesterol [editorial]? J Am Coll Cardiol 2009;55:42-4.
    • (2009) J Am Coll Cardiol , vol.55 , pp. 42-44
    • Robinson, J.G.1
  • 30
    • 67849129098 scopus 로고    scopus 로고
    • Omega-3 polyunsaturated fatty acids and cardiovascular diseases
    • Lavie CJ, Milani RV, Mehra MR, et al. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol 2009;54: 585-94.
    • (2009) J Am Coll Cardiol , vol.54 , pp. 585-594
    • Lavie, C.J.1    Milani, R.V.2    Mehra, M.R.3
  • 32
    • 78651350459 scopus 로고    scopus 로고
    • Reduction in the incidence of type 2 diabetes with the Mediterranean Diet: Results of the PREDIMED- Reus Nutrition Intervention Randomized trial
    • Salas-Salvadó J, Bullo M, Babio N, et al. Reduction in the incidence of type 2 diabetes with the Mediterranean Diet: results of the PREDIMED- Reus Nutrition Intervention Randomized trial. Diabetes Care 2011;34:14-9.
    • (2011) Diabetes Care , vol.34 , pp. 14-19
    • Salas-Salvadó, J.1    Bullo, M.2    Babio, N.3
  • 33
    • 78649427571 scopus 로고    scopus 로고
    • Effects of aerobic and resistance training on hemoglobin A1c levels in patients with Type 2 diabetes: A randomized controlled trial
    • Church TS, Blair SN, Cocreham S, et al. Effects of aerobic and resistance training on hemoglobin A1c levels in patients with Type 2 diabetes: a randomized controlled trial. JAMA 2010:304:2253-62.
    • (2010) JAMA , vol.304 , pp. 2253-2262
    • Church, T.S.1    Blair, S.N.2    Cocreham, S.3
  • 34
    • 64749101185 scopus 로고    scopus 로고
    • Exercise training and cardiac rehabilitation in primary and secondary prevention of coronary heart disease
    • Lavie CJ, Thomas RJ, Squires RW, et al. Exercise training and cardiac rehabilitation in primary and secondary prevention of coronary heart disease. Mayo Clin Proc 2009;84:373-83.
    • (2009) Mayo Clin Proc , vol.84 , pp. 373-383
    • Lavie, C.J.1    Thomas, R.J.2    Squires, R.W.3
  • 37
    • 79959837992 scopus 로고    scopus 로고
    • Impact of physical activity, cardiorespiratory fitness, and exercise training on markers of inflammation
    • [published online ahead of print March 21, 2011] doi: 10.1097/HCR.0b013e3182122827
    • Lavie CJ, Church TS, Milani RV, et al. Impact of physical activity, cardiorespiratory fitness, and exercise training on markers of inflammation [published online ahead of print March 21, 2011]. J Cardiopulm Rehabil Prev doi: 10.1097/HCR.0b013e3182122827.
    • J Cardiopulm Rehabil Prev
    • Lavie, C.J.1    Church, T.S.2    Milani, R.V.3
  • 39
    • 0037420492 scopus 로고    scopus 로고
    • Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial
    • DOI 10.1016/S0140-6736(03)12948-0
    • Sever PS, Dahlof B, Poulter NR, et al. ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003;361:1149-58. (Pubitemid 36398384)
    • (2003) Lancet , vol.361 , Issue.9364 , pp. 1149-1158
    • Sever, P.S.1    Dahlof, B.2    Poulter, N.R.3    Wedel, H.4    Beevers, G.5    Caulfield, M.6    Collins, R.7    Kjeldsen, S.E.8    Kristinsson, A.9    McInnes, G.T.10    Mehlsen, J.11    Nieminen, M.12    O'Brien, E.13    Ostergren, J.14
  • 40
    • 72549118057 scopus 로고    scopus 로고
    • Beyond low-density lipoprotein cholesterol: Respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/highdensity lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women
    • Arsenault BJ, Rana JS, Stroes ES, et al. Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/highdensity lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J Am Coll Cardiol 2009;55:35-41.
    • (2009) J Am Coll Cardiol , vol.55 , pp. 35-41
    • Arsenault, B.J.1    Rana, J.S.2    Stroes, E.S.3
  • 41
    • 34248159606 scopus 로고    scopus 로고
    • Statin wars - Emphasis on potency vs event reduction and safety?
    • Lavie CJ, Milani RV, O'Keefe JH. Statin wars: emphasis on potency vs event reduction and safety? Mayo Clin Proc 2007;82:539-42. (Pubitemid 46709420)
    • (2007) Mayo Clinic Proceedings , vol.82 , Issue.5 , pp. 539-542
    • Lavie, C.J.1    Milani, R.V.2    O'Keefe, J.H.3
  • 42
    • 77949334766 scopus 로고    scopus 로고
    • High-dose atorvastatin in acute coronary and cerebrovascular syndromes
    • Lavie CJ, Milani RV. High-dose atorvastatin in acute coronary and cerebrovascular syndromes. J Am Coll Cardiol Intv 2010;3:340-2.
    • (2010) J Am Coll Cardiol Intv , vol.3 , pp. 340-342
    • Lavie, C.J.1    Milani, R.V.2
  • 45
    • 0023726344 scopus 로고
    • Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study
    • Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988;260:641-51.
    • (1988) JAMA , vol.260 , pp. 641-651
    • Manninen, V.1    Elo, M.O.2    Frick, M.H.3
  • 47
    • 28044452217 scopus 로고    scopus 로고
    • Effects of longterm fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial
    • Keech A, Simes RJ, Barter P, et al. Effects of longterm fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366:1849-61.
    • (2005) Lancet , vol.366 , pp. 1849-1861
    • Keech, A.1    Simes, R.J.2    Barter, P.3
  • 48
    • 77951704587 scopus 로고    scopus 로고
    • Effects of combination lipid therapy in type 2 diabetes mellitus
    • for the ACCORD Study Group
    • Ginsberg HN, Elam MB, Lovato LC, et al; for the ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74.
    • (2010) N Engl J Med , vol.362 , pp. 1563-1574
    • Ginsberg, H.N.1    Elam, M.B.2    Lovato, L.C.3
  • 49
    • 0035328230 scopus 로고    scopus 로고
    • Niacin in patients with diabetes mellitus and coronary artery disease
    • PII S0002914901015417
    • Lavie CJ, Milani RV. Niacin in patients with diabetes mellitus and coronary artery disease. Am J Cardiol 2001;87:1137-8. (Pubitemid 32710341)
    • (2001) American Journal of Cardiology , vol.87 , Issue.9 , pp. 1137-1138
    • Lavie, C.J.1    Milani, R.V.2
  • 50
    • 0034644442 scopus 로고    scopus 로고
    • Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: The ADMIT study: A randomized trial
    • for the ADMIT Investigators
    • Elam MB, Hunninghake DB, Davis KB, et al; for the ADMIT Investigators. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. JAMA 2000;284:1263-70.
    • (2000) JAMA , vol.284 , pp. 1263-1270
    • Elam, M.B.1    Hunninghake, D.B.2    Davis, K.B.3
  • 52
    • 11844304073 scopus 로고    scopus 로고
    • Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project)
    • DOI 10.1016/j.amjcard.2004.09.013, PII S0002914904015334
    • Canner PL, Furberg CD, Terrin ML, et al. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2005;95:254-7. (Pubitemid 40092094)
    • (2005) American Journal of Cardiology , vol.95 , Issue.2 , pp. 254-257
    • Canner, P.L.1    Furberg, C.D.2    Terrin, M.L.3    McGovern, M.E.4
  • 53
    • 0027077502 scopus 로고
    • Marked benefit with sustained-release niacin therapy in patients with 'isolated' very low levels of high-density lipoprotein cholesterol and coronary artery disease
    • DOI 10.1016/0002-9149(92)90868-Y
    • Lavie CJ, Mailander L, Milani RV. Marked benefit with sustainedrelease niacin therapy in patients with "isolated" very low levels of high-density lipoprotein cholesterol and coronary artery disease. Am J Cardiol 1992;69:1083-5. (Pubitemid 23059008)
    • (1992) American Journal of Cardiology , vol.69 , Issue.12 , pp. 1083-1085
    • Lavie, C.J.1    Mailander, L.2    Milani, R.V.3
  • 54
    • 10044281651 scopus 로고    scopus 로고
    • Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins
    • Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-7.
    • (2004) Circulation , vol.110 , pp. 3512-3517
  • 55
    • 72049129430 scopus 로고    scopus 로고
    • Extended-release niacin or ezetimibe and carotid intima-media thickness
    • Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009;361: 2113-22.
    • (2009) N Engl J Med , vol.361 , pp. 2113-2122
    • Taylor, A.J.1    Villines, T.C.2    Stanek, E.J.3
  • 57
    • 0023001772 scopus 로고
    • Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin
    • Canner PI, Berge KG, Wenger NK, et al. Fifteen-year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55. (Pubitemid 17208898)
    • (1986) Journal of the American College of Cardiology , vol.8 , Issue.6 , pp. 1245-1255
    • Canner, P.L.1    Berge, K.G.2    Wenger, N.K.3
  • 58
    • 0023910325 scopus 로고
    • Reduction of mortality in the Stockholm ischaemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid
    • Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm ischaemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988;223:405-18.
    • (1988) Acta Med Scand , vol.223 , pp. 405-418
    • Carlson, L.A.1    Rosenhamer, G.2
  • 59
    • 0021350001 scopus 로고
    • The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease
    • The Lipid Research Clinics Coronary Primary Prevention Trial T investigators
    • The Lipid Research Clinics Coronary Primary Prevention Trial T investigators. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64.
    • (1984) JAMA , vol.251 , pp. 351-364
  • 60
    • 33947120281 scopus 로고    scopus 로고
    • Results of the glucose-lowering effect of WelChol study (GLOWS): A randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes
    • DOI 10.1016/j.clinthera.2007.01.003, PII S0149291807000173
    • Zieve FJ, Kalin MF, Schwartz SL, et al. Results of the glucoselowering effect of WelChol study (GLOWS): a randomized, doubleblind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 2007;29:74-83. (Pubitemid 46414026)
    • (2007) Clinical Therapeutics , vol.29 , Issue.1 , pp. 74-83
    • Zieve, F.J.1    Kalin, M.F.2    Schwartz, S.L.3    Jones, M.R.4    Bailey, W.L.5
  • 61
    • 33645735636 scopus 로고    scopus 로고
    • Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia
    • Bays HE, Davidson M, Jones MR, et al. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol 2006;97:1198-205.
    • (2006) Am J Cardiol , vol.97 , pp. 1198-1205
    • Bays, H.E.1    Davidson, M.2    Jones, M.R.3
  • 62
    • 70450199759 scopus 로고    scopus 로고
    • Rediscovering bile acid sequestrants
    • Bell DS, O'Keefe JH. Rediscovering bile acid sequestrants. Diabetes Obes Metab 2009;11:1114-21.
    • (2009) Diabetes Obes Metab , vol.11 , pp. 1114-1121
    • Bell, D.S.1    O'Keefe, J.H.2
  • 63
    • 79551673658 scopus 로고    scopus 로고
    • Strategies for optimizing glycemic control and cardiovascular prognosis in type 2 diabetes mellitus
    • O'Keefe JH, Abuannadi M, Lavie CJ, et al. Strategies for optimizing glycemic control and cardiovascular prognosis in type 2 diabetes mellitus. Mayo Clin Proc 2011;86:128-38.
    • (2011) Mayo Clin Proc , vol.86 , pp. 128-138
    • O'Keefe, J.H.1    Abuannadi, M.2    Lavie, C.J.3
  • 64
    • 64749096151 scopus 로고    scopus 로고
    • Impact of ezetimibe on atherosclerosis: Is the jury still out?
    • Badarin FJ, Kullo IJ, Kopecky SL, et al. Impact of ezetimibe on atherosclerosis: is the jury still out? Mayo Clin Proc 2009;84:353-61.
    • (2009) Mayo Clin Proc , vol.84 , pp. 353-361
    • Badarin, F.J.1    Kullo, I.J.2    Kopecky, S.L.3
  • 66
    • 49249089489 scopus 로고    scopus 로고
    • Intensive lipid intervention in the post-ENHANCE era
    • O'Keefe JH, Bybee KA, Lavie CJ. Intensive lipid intervention in the post-ENHANCE era. Mayo Clin Proc 2008;83:867-9.
    • (2008) Mayo Clin Proc , vol.83 , pp. 867-869
    • O'Keefe, J.H.1    Bybee, K.A.2    Lavie, C.J.3
  • 67
    • 67549125150 scopus 로고    scopus 로고
    • The gravity of JUPITER (justification for the use of statins in primary prevention: An intervention trial evaluating rosuvastatin)
    • O'Keefe JH, Carter MD, Lavie CJ, et al. The gravity of JUPITER (justification for the use of statins in primary prevention: an intervention trial evaluating rosuvastatin). Postgrad Med 2009;121:113-8.
    • (2009) Postgrad Med , vol.121 , pp. 113-118
    • O'Keefe, J.H.1    Carter, M.D.2    Lavie, C.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.